Any future trials or real-world evidence examining the combination or sequencing of these therapies, or the comparative efficacy or safety of these treatment options, will provide useful information for evolving the clinical management of early-stage, HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.